sutirem 12.5mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - sunitinib - capsule,hard - 12.5mg - sunitinib (8000003189) 12,5mg
sutirem 37.5mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - sunitinib - capsule,hard - 37.5mg - sunitinib (8000003189) 37,5mg
sutirem 25mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - sunitinib - capsule,hard - 25mg - sunitinib (8000003189) 25mg
sutirem 50mg capsule,hard
remedica ltd (0000003171) aharnon str., lemesos, 3056 - sunitinib - capsule,hard - 50mg - sunitinib (8000003189) 50mg
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Αντινεοπλασματικοί παράγοντες - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sun-de3® oral.sol 25000 iu/ml
nassington ltd, cyprus Ιπποκράτους 3Α,, 2006 Λευκωσία - cholecalciferol concentrate - oral.sol (ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 25000 iu/ml - cholecalciferol concentrate 25mg - colecalciferol
sun-de3® or.so.d 10000 iu/ml
nassington ltd, cyprus Ιπποκράτους 3Α,, 2006 Λευκωσία - cholecalciferol concentrate - or.so.d (ΠΟΣΙΜΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ) - 10000 iu/ml - cholecalciferol concentrate 10mg - colecalciferol
sun-de3® oral.sol 100000 iu/ml
nassington ltd, cyprus Ιπποκράτους 3Α,, 2006 Λευκωσία - cholecalciferol concentrate - oral.sol (ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 100000 iu/ml - cholecalciferol concentrate 100mg - colecalciferol
sutent caps 50mg/cap
pfizer ΕΛΛΑΣ Α.Ε. Μεσογείων 243,, 154 51 154 51, Νέο Ψυχικό 210.6785800 - sunitinib - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 50mg/cap - sunitinib
inlyta
pfizer europe ma eeig - axitinib - Καρκίνωμα, Νεφρικό κύτταρο - Αναστολείς πρωτεϊνικής κινάσης - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.